Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
- Dow Jones Citing Interview
Argus Research analyst Jasper Hellweg maintains AstraZeneca (NASDAQ:AZN) with a Buy and raises the price target from $80 to ...
Goldman Sachs analyst Rajan Sharma initiates coverage on AstraZeneca (NASDAQ:AZN) with a Buy rating and announces Price Targ...
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjuga...
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare d...
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patient...
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medi...
